Completed PHASE2 INTERVENTIONAL 15-arm NCT02202980

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (LEPTON)

A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

Sponsor: Gilead Sciences

Conditions Chronic Hepatitis C

Interventions LDV/SOF RBV SOF/VEL VOX

Updated 8 times since 2017 Last updated: Oct 19, 2018 Started: Aug 4, 2014 Primary completion: Mar 16, 2016 Completion: May 9, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02202980, this PHASE2 trial focuses on Chronic Hepatitis C and remains completed. Sponsored by Gilead Sciences, it has been updated 8 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Dec 2018 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Dec 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gilead Sciences

Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Auckland, New Zealand
• Christchurch, New Zealand